Curetis
OpGen Q1 Revenues Rise 34 Percent on Combination With Curetis
OpGen said it is awaiting a clearance decision for its Unyvero pneumonia cartridge in China, where it is currently under review and pending approval.
OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval
The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.
OpGen Posts 70 Percent Increase in Q3 Revenues Amid Shuffling of Portfolio
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
Multiplex PCR Panels for Joint Infections on the Horizon
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
OpGen Posts 54 Percent Increase in Preliminary Q3 Revenues, Consolidates Product Portfolio
Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.
Aug 20, 2020
OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit
Aug 12, 2020
OpGen Q2 Revenues Climb 20 Percent
May 7, 2020
OpGen Q1 Revenues Drop 38 Percent
Apr 14, 2020
OpGen Q1 Preliminary Revenues Down 38 Percent
Mar 24, 2020
OpGen Fourth Quarter Revenues Increase 8 Percent
Feb 20, 2020
Curetis Preliminary 2019 Revenues Up 64 Percent
Feb 12, 2020
OpGen Preliminary 2019 Revenues up 19 Percent
Nov 6, 2019
OpGen Posts 17 Percent Increase in Q3 Revenues
Oct 24, 2019
OpGen Prices $9.4M Stock, Warrant Offering
Oct 21, 2019